Payment overview · 2025
General Payments
$1,442.27
73 reported records · 25 companies
Healthcare provider profile · identity verified
Daniel Tavari, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · THOUSAND OAKS, CA · NPI 1942240213
Verified facts
What the public records show
CMS Open Payments records show Daniel Tavari, D.O. received $1,442.27 in general payments during 2025 across 73 reported records.
ABBVIE INC. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Linzess, Shingrix, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $226.25 | 15.7% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $212.67 | 14.8% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $95.40 | 6.6% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $86.98 | 6.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $85.15 | 5.9% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $72.28 | 5.0% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $69.24 | 4.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.18 | 4.7% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $67.16 | 4.7% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.37 | 3.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.53 | 3.5% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $36.54 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.05 | 2.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.89 | 2.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.91 | 2.3% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $31.59 | 2.2% | 2 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $30.01 | 2.1% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.95 | 2.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $23.71 | 1.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.66 | 1.3% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.82 | 1.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.34 | 1.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.89 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.05 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.65 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,442.27 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $157.76 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $120.84 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $86.98 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $83.23 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.47 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $72.28 | 4 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $72.28 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $69.24 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $67.16 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.39 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.39 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $60.09 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $56.37 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $53.44 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $53.44 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.53 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.53 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.53 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.51 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.42 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $36.54 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $34.01 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.91 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.71 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.07 | 1 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $30.01 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $28.95 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 44 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 32 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 55 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
44 | 44 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
32 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
262 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 686 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 85 |
| Losartan Potassium | Losartan Potassium | 336 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 325 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 72 |
| Furosemide | Furosemide | 288 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 71 |
| Eliquis | Apixaban | 262 | 43 |
| Omeprazole | Omeprazole | 245 | 53 |
| Potassium Chloride | Potassium Chloride | 220 | 46 |
| Famotidine | Famotidine | 204 | 55 |
| Gabapentin | Gabapentin | 195 | 44 |
| Allopurinol | Allopurinol | 181 | 52 |
| Ezetimibe | Ezetimibe | 178 | 45 |
| Metformin Hcl | Metformin Hcl | 174 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 41 |
| Metformin Hcl Er | Metformin Hcl | 152 | 45 |
| Finasteride | Finasteride | 145 | 37 |
| Alprazolam | Alprazolam | 137 | 27 |
| Pregabalin | Pregabalin | 124 | 24 |
| Mirtazapine | Mirtazapine | 122 | 31 |
| Ibandronate Sodium | Ibandronate Sodium | 121 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 113 | 21 |
| Donepezil Hcl | Donepezil Hcl | 111 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 33 |
| Lisinopril | Lisinopril | 108 | 35 |
| Trazodone Hcl | Trazodone Hcl | 106 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 34 |
| Xarelto | Rivaroxaban | 104 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 18 |
| Clonazepam | Clonazepam | 101 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 29 |
| Montelukast Sodium | Montelukast Sodium | 95 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 29 |
| Januvia | Sitagliptin Phosphate | 87 | 15 |
| Simvastatin | Simvastatin | 87 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 26 |
| Glimepiride | Glimepiride | 85 | 19 |
| Carvedilol | Carvedilol | 79 | 20 |
| Spironolactone | Spironolactone | 78 | 14 |
| Memantine Hcl | Memantine Hcl | 76 | 12 |
| Alendronate Sodium | Alendronate Sodium | 70 | 17 |
| Prednisone | Prednisone | 70 | 46 |
| Sertraline Hcl | Sertraline Hcl | 70 | 20 |
| Ozempic | Semaglutide | 69 | 15 |
| Meloxicam | Meloxicam | 67 | 38 |
| Tramadol Hcl | Tramadol Hcl | 64 | 17 |
| Cephalexin | Cephalexin | 62 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 18 |
| Jardiance | Empagliflozin | 61 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 12 |
| Synthroid | Levothyroxine Sodium | 55 | 16 |
| Lorazepam | Lorazepam | 54 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Azithromycin | Azithromycin | 48 | 42 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 48 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 44 | 44 |
| Cefdinir | Cefdinir | 43 | 39 |
| Digoxin | Digoxin | 43 | 15 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 42 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | 17 |
| Ketoconazole | Ketoconazole | 42 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 13 |
| Celecoxib | Celecoxib | 39 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Tradjenta | Linagliptin | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 11 |
| Bethanechol Chloride | Bethanechol Chloride | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 19 |
| Testosterone | Testosterone | 34 | 14 |
| Bumetanide | Bumetanide | 33 | 12 |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | 12 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 13 |
| Temazepam | Temazepam | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Entacapone | Entacapone | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Clarithromycin | Clarithromycin | 21 | 20 |
| Clonidine | Clonidine | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Folic Acid | Folic Acid | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Triazolam | Triazolam | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,442.27 · 73 records | ABBVIE INC. | ABRYSVO, ALVESCO, AMVUTTRA, AREXVY, AUSTEDO XR, Adzenys XR-ODT, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, DUPIXENT, ENFLONSIA, EVENITY, Fabhalta, GARDASIL 9, Intracept, JARDIANCE, KRYSTEXXA, Korlym, LEQVIO, LINZESS, M-M-R II, OTEZLA, PREVNAR 20, PROLIA, Prolastin-C Liquid, QULIPTA, REPATHA, REXULTI, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, TZIELD, Tymlos, UBRELVY, VAXNEUVANCE, VOQUEZNA, VOWST, VRAYLAR, Veozah, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error